What question did this study set out to answer?

This review aims to evaluate the role and effectiveness of monoclonal antibodies in treating Castleman disease, particularly idiopathic multicentric Castleman disease.

July 11, 2026Expert Opinion on Biological Therapy

Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies

View Full Paper

Ask AI

Bookmark

This review aims to evaluate the role and effectiveness of monoclonal antibodies in treating Castleman disease, particularly idiopathic multicentric Castleman disease.
Literature search of PubMed/MEDLINE from inception to May 2026
Focus on monoclonal antibodies including siltuximab, tocilizumab, and rituximab
Review of clinical trials, consensus guidelines, real-world cohorts, and mechanistic studies.
IL-6 blockade is established as the mainstay treatment for idiopathic multicentric Castleman disease (iMCD).
Rituximab is crucial for HHV-8-associated MCD and plays a role in managing iMCD such as idiopathic plasmacytic lymphadenopathy (IPL).
Future strategies may involve biomarker-driven treatment and subtype-specific approaches for conditions like iMCD-TAFRO.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review discusses monoclonal antibody efficacy for Castleman disease, indicating evolving treatment strategies.

Cite This Study

Nishimura et al. (2026) studied this question.

synapsesocial.com/papers/6a51deadc18d7f28ca5004e8 https://doi.org/10.1080/14712598.2026.2702010

View Full Paper

Ask AI

Bookmark

Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies

Key Points

Discussion

Implication

Cite This Study

Treating Castleman disease: insights into the use and efficacy of monoclonal antibodies

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider